Agree. Progress comes from the few who refuse to accept the status quo. Everyone else benefits.
In medicine that has always been the scientists and drug developers who refused to accept disease as inevitable, from penicillin to modern vaccines and cancer therapies.
AI may help us discover more drug candidates. But that won’t help patients if they get stuck waiting for a clinical trial.
The next bottleneck in drug discovery may not be discovery at all. It may be our ability to test the science. This is an important look at how AI could make development faster and less expensive while preserving the human judgment and safety oversight that trials require.
More shots on goal only matter if we can get the best ones to patients.
One of the harder parts of leadership is knowing when to step back so someone else can step up.
It’s easy to stay in the middle of decisions because you can move faster or because the stakes feel high. But every time you do, you take away a chance for someone on your team to practice judgment.
Judgment doesn’t come from watching. It comes from owning the outcome, working through the setbacks, and learning what actually matters.
I’ve always thought of business as a team sport. The goal isn’t to be the person who makes every call. It’s to leave the company with people who can make good ones without you.
What decision did you keep this week that you could have given away?
I’m looking for a Chief Customer Officer for a startup I’m involved with.
We need a hands-on leader who can build an exceptional experience for both consumers and professional partners, create a customer-first culture and turn that into a real competitive advantage.
If someone comes to mind, please DM me.
Your heart, brain and muscles don’t all age at the same speed. So why do we talk about aging as if they do?
This paper makes the case for a more personalized approach: find where someone is most vulnerable and look for ways to intervene before disease takes hold.
The goal shouldn’t just be a younger number on a test. It should be more healthy, independent years.
pnas.org/doi/10.1073/pnas.26…
It’s understandable why so many companies chase the same drug targets. Once the biology is validated, the risk can be lower and the odds of success better. Competition can also produce better medicines.
But if we all follow the same trail, who takes on the diseases where the biology is still uncharted?
As I said in my last post, AI could help make more diseases worth pursuing. The real opportunity is to use it to better understand disease, identify novel targets and take intelligent risks on unmet needs. That’s how we get beyond more drugs for the same targets and bring new hope to more patients.
The comparison between blockbuster drugs and software companies is interesting. But the biggest opportunity for AI in pharma may not be creating bigger blockbusters. It may be making more diseases worth pursuing.
If we can improve the odds of success and reduce the time and cost of development, we can potentially bring treatments to patients who have been overlooked because the science was too hard or the market too small.
That would be good business. More importantly, medicines improve and save lives.
The market for drugs is deep and diversified, and the size of the prize is huge if you get it right. A single blockbuster drug can generate annual revenue on the scale of a major software company.
Pharma has unusual economics – it's a hits business in drug development and an annuity business once a drug succeeds.
AI could change both by improving the odds of success and simultaneously decreasing development time and cost.
Full piece on why AI will make pharma even bigger: a16z.news/p/big-pharma-can-r…
Being called “indispensable” may be flattering to a CEO. It should make the board nervous.
Building talent and preparing the next generation of leaders are core responsibilities of the job. You can’t wait until someone announces a departure to start thinking about succession.
And a list of names in a board presentation isn’t a plan. Give people real responsibility. Let them make decisions, work through setbacks and develop their own judgment. Make sure the board knows them beyond a rehearsed annual presentation.
The next CEO may need different strengths than yours. That’s worth remembering before you start looking for someone who thinks exactly like you.
I’ve always viewed business as a team sport. A strong CEO should want the company to keep winning after they leave.
Leaving a company better than you found it means more than better financial results. It means leaving behind people capable of taking it further.
wsj.com/business/they-were-t…
China doesn’t just want to develop the next generation of medicines. It wants to keep ownership of the technology behind them.
Its proposed export restrictions could change how global pharma accesses Chinese innovation. This isn’t a blanket ban on drug exports. It targets certain technology platforms, while still allowing important paths to license individual products.
I would expect more licensing deals and fewer acquisitions of the affected platforms. China may retain more of the long-term upside, but there’s a trade-off. Fewer potential buyers could make these companies harder to finance. Protecting an asset and making it more valuable aren’t always the same thing.
For global pharma, uncertainty has a cost. Can you get the rights you need? Can you transfer the technology and manufacture where you need to? Those questions will affect what investors are willing to pay and which programs get funded.
And we shouldn’t assume that making Chinese innovation harder to access automatically brings capital back to American biotech. Investors have other choices.
The US should address genuine security risks while making this the best place in the world to develop medicines. That means faster, more efficient trials, predictable regulation, reliable manufacturing and a market that rewards meaningful innovation.
My concern is that we end up spending more money duplicating capabilities and less money advancing treatments. We should compete to make better medicines, not make it harder for patients to get them.
nature.com/articles/s41587-0…
Last night’s Sparkle of Hope was a great success for @CommunityHopeNJ Last night’s Sparkle of Hope was a great success for Community Hope. I’m proud to chair an evening that raised funds to help veterans facing homelessness and people living with mental illness find housing, support and a path forward.
Thank you to everyone who came, our generous sponsors and the Community Hope team who do this work every day. Especially on Veterans Day, it was a reminder that thanking people for their service has to include being there when they need us.. I’m proud to chair an evening that raised funds to help veterans facing homelessness and people living with mental illness find housing, support and a path forward.
Thank you to everyone who came, our generous sponsors and the Community Hope team who do this work every day. Especially on Veterans Day, it was a reminder that thanking people for their service has to include being there when they need us.
Thank you to all who have served our country. On Veterans Day, I’m honored to chair tonight’s Sparkle of Hope Gala for @CommunityHopeNJ helping veterans and their families find housing and support. Every veteran deserves a safe place to call home.
A cheap drug is no bargain if patients can’t get it. Innovation is costly and risky, but patients still need prices they can afford.
We need a more equitable global system, where wealthy nations support innovation and more patients can access those medicines when needed.
wsj.com/health/pharma/trumps…
Drug development is hard. These two heart drug failures are a reminder that even when a medicine does what it was designed to do, that doesn’t always translate into a benefit for patients.
I’m optimistic AI can help us better understand the biology, challenge our assumptions earlier and design smarter clinical trials. If it helps us know sooner which ideas won’t work, that’s progress too.
But biology still gets the final vote. The real test is whether we can turn promising science into medicines that safely help patients.
nytimes.com/2026/11/07/scien…
What if the biggest contribution AI makes to drug discovery isn’t finding more possible drug candidates, but helping us decide which experiments to run and which programs to stop?
This article from @AnthropicAI got me thinking. AI could help scientists compare competing explanations for a disease and design experiments to test them. That’s a much more interesting use of AI than simply generating a longer list of hypotheses.
Of course, the models still need to be tested in the lab and eventually in patients. A convincing explanation isn’t the same as a proven one.
The real prize is better decisions, fewer dead ends and, hopefully, better medicines reaching patients faster.
New on our Science Blog: How AI is beginning to change scientific modeling.
Scientific models help researchers explain and predict real-world systems—like how a single nerve cell fires, or what happens when neutron stars collide. Recent advances have transformed how scientists fit complex models to data. But scientists still typically write the models manually, and usually need to weigh up several competing versions, each of which might explain the data in a different way.
In a guest post, Jakob Macke, Daniel Gedon, and Stefan Wahl describe how AI is starting to help with these parts of the process. By writing, running, fitting, and revising scientific models as code, AI can explore many possible model structures, and find out which explanations the data support.
anthropic.com/research/teach…
I’ve found that some of the loneliest moments in leadership come when you’re weighing a consequential decision and there’s no obvious right answer. You can listen to your team and seek advice, but ultimately you have to make the call and live with it.
That’s where a good, experienced board member can make a real difference. Someone you trust enough to share your doubts with, who has been there before and can help you think it through.
You can have a room full of A players and still have a mediocre team.
The difference is whether people know what winning looks like, trust each other to deliver and can speak up when something isn’t working.
As a leader, be clear about the goal. Give people real responsibility. Get the obstacles out of their way.
Then let them do what you hired them to do.
We want an extra 20 years. Just don’t ask us to change what we’re doing tonight.
That’s the awkward part of the longevity conversation. A new pill gets our attention. An earlier bedtime feels like a sacrifice.
I’m excited about the breakthroughs ahead. But how much of the demand for an “easy button” is really a request to keep our habits and lose the consequences?
10
1,397
The AI world calls it recursive self-improvement. In business, I’ve always thought the real test of a leader was whether the team kept getting better without needing more of the leader.
Great people make the people around them better. A mistake changes how the team works. A win raises expectations. Over time, the whole company becomes harder to compete with.
But that takes a culture where people can challenge the boss, own a bad decision and keep working through a problem when the easy answers run out. Grit matters. So does knowing when persistence has turned into stubbornness.
Now put increasingly capable AI in the hands of a team like that.
I’d spend less time worrying about which company has the best AI tools and more time worrying about which company is learning fastest.
wsj.com/tech/ai/ai-anthropic…
AI can make drug discovery cheaper, but a promising drug candidate can still become a very expensive failure.
As AI gives us more candidates, knowing which ones deserve years of clinical work and serious capital becomes even more valuable. Those are consequential calls, and a longer pipeline doesn’t make them any easier.
I’d like to see the same ambition we’re bringing to discovery applied to shortening clinical development and regulatory review. Saving time at the beginning should push us to tackle the years that follow.
I’m encouraged by how quickly the science is advancing. But the patient waiting for treatment needs that science to become an approved medicine they can actually use.
It is coming, although @elonmusk and I may have different things in mind.
I’m excited about what science could do for how we age. That’s even more reason to take sleep, diet and exercise seriously today. Myself included. We should be giving ourselves the best chance to be around and benefit from the breakthroughs ahead.
I’d like to give the science a little less repair work when it gets here.😂
5
28
2,152











